首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies
【24h】

Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies

机译:具有1-二烯丙基-1,2-二醇盐一氧化氮供体部分的新型抗癌冬凌草甲素衍生物:设计,合成,生物学评估和一氧化氮释放研究

获取原文
获取原文并翻译 | 示例
           

摘要

Oridonin (1) is a complex ent-kaurane diterpenoid with unique antitumor profile, which is isolated from Isodon rubescens. In order to develop novel derivatives of oridonin with improved potency, a series of nitric oxide (NO)-releasing oridonin derivatives were synthesized by coupling diazeniumdiolates with oridonin and its semisynthesized analogues. Their in vitro antiproliferative activity, nitric oxide release ability, and preliminary anticancer mechanism were further evaluated. The results displayed that all the target compounds exhibited potent antiproliferative activities, with IC50 values ranging from 1.84 to 17.01 mu M. Besides, it was observed that in most cases, the antiproliferative activity correlated well with levels of intracellular NO release. More interestingly, preliminary mechanism studies revealed that the most potent compound 14d induced apoptosis and arrested the cell cycle at the S phase in Bel-7402 cells, which is different from parent compound oridonin. Together, the above promising results warrant the further development of oridonin/NO hybrids as potential antitumor leads. (C) 2016 Elsevier Ltd. All rights reserved.
机译:冬凌草甲素(1)是一种复杂的对映型月桂烷双萜类化合物,具有独特的抗肿瘤特性,可从冬凌草(Isodon rubescens)中分离出来。为了开发具有更高效能的冬凌草甲素的新型衍生物,通过将二醇二氮烯鎓盐与冬凌草甲素及其半合成类似物偶联,合成了一系列释放一氧化氮(NO)的冬凌草甲素。进一步评估了它们的体外抗增殖活性,一氧化氮释放能力和初步的抗癌机制。结果表明,所有目标化合物均显示出有效的抗增殖活性,IC50值为1.84至17.01μM。此外,观察到,在大多数情况下,抗增殖活性与细胞内NO释放水平密切相关。更有趣的是,初步的机制研究表明,最有效的化合物14d诱导了Bel-7402细胞的凋亡,并使细胞周期停滞在S期,这不同于母体化合物oridonin。总之,上述有希望的结果保证了作为潜在的抗肿瘤药物的冬凌草甲素/ NO杂化物的进一步发展。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号